Back

Human Metapneumovirus seroprevalence and PCR trends - Findings from a Tertiary Care Hospital in India.

Yelamanchili, S.; Gujjarlapudi, D.; Chella, N.; B, S. Y.; Dulla, V. R.; Duvvur, N. r.

2025-02-17 infectious diseases
10.1101/2025.02.12.25322117
Show abstract

Human Metapneumovirus (hMPV) is a paramyxovirus that was detected in India first in 2004. It causes a mild common cold in most cases but serious illness has been reported in some young children, adults >65 years and the immunocompromised. AIMTo study the age related prevalence of IgG antibodies in the population and also to determine the percent positivity and seasonal variation of hMPV infection. MATERIAL AND METHODSThis cross-sectional study assessed seroprevalence by testing 820 serum samples collected between January 25th - 31st 2025 for hMPV IgG antibodies by ELISA and stratified according to age and sex. hMPV PCR trends: Retrospective data from the 1276 tests for Respiratory Viruses done at our centre during 2023 and 2024 were analysed and comprised of age groups 0-18, 19-30 ,31-45, 45-60 and > 60 years. The relationship between gender (M/F) and outcome (positive/negative) across various age groups was analysed using the chi-square test for independence in Graph Pad Prism 8.0. RESULTS: Seroprevalence studyOverall hMPV IgG Antibody Positivity was 53.4%. Antibody positivity was higher in above 60 years when compared to other groups and was statistically significant (P=0.0001) and female predominance is seen. In hMPV PCR trendsA higher percentage of positivity were observed in > 60years individuals who had hospitalisation when compared to the other groups which was statistically significant(P=0.0001). Overall Percent positivity was 7.8% in 2023 and 3.8% in 2024. Seasonal peaks occurred in Feb-Mar and Oct. 92.6% of patients were discharged and doing well on follow-up and only 7.4% deaths were seen. CONCLUSIONOur findings highlight around 53.4% of the total study population had hMPV IgG antibodies. PCR positivity and antibody positivity was higher in individuals over 60 who had other comorbidities. Hospitalization and mortality rates are significantly high in this high risk groups. Vaccine development for high-risk individuals is recommended.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
PLOS ONE
based on 1737 papers
Top 41%
12.5%
2
Journal of Medical Virology
based on 95 papers
Top 1.0%
7.5%
3
Scientific Reports
based on 701 papers
Top 34%
5.3%
4
BMC Infectious Diseases
based on 110 papers
Top 1%
4.7%
5
Cureus
based on 64 papers
Top 4%
4.5%
6
BMJ Open
based on 553 papers
Top 25%
4.5%
7
International Journal of Infectious Diseases
based on 115 papers
Top 2%
4.5%
8
PLOS Neglected Tropical Diseases
based on 166 papers
Top 4%
3.8%
9
Journal of Infection
based on 64 papers
Top 1%
2.8%
50% of probability mass above
10
Journal of Clinical Virology
based on 54 papers
Top 1%
2.5%
11
IJID Regions
based on 10 papers
Top 0.1%
2.3%
12
Frontiers in Medicine
based on 99 papers
Top 9%
2.2%
13
PLOS Global Public Health
based on 287 papers
Top 13%
2.2%
14
Open Forum Infectious Diseases
based on 124 papers
Top 5%
1.8%
15
Clinical Infectious Diseases
based on 219 papers
Top 14%
1.6%
16
Epidemiology and Infection
based on 80 papers
Top 5%
1.6%
17
Journal of Family Medicine and Primary Care
based on 10 papers
Top 0.8%
1.6%
18
Frontiers in Cellular and Infection Microbiology
based on 22 papers
Top 2%
1.6%
19
EClinicalMedicine
based on 21 papers
Top 0.6%
1.3%
20
Emerging Infectious Diseases
based on 84 papers
Top 8%
1.3%
21
Eurosurveillance
based on 77 papers
Top 6%
1.3%
22
The American Journal of Tropical Medicine and Hygiene
based on 50 papers
Top 7%
1.3%
23
Journal of Infection and Public Health
based on 15 papers
Top 2%
0.8%
24
Clinical Microbiology and Infection
based on 54 papers
Top 6%
0.7%
25
Journal of Hospital Infection
based on 21 papers
Top 3%
0.7%
26
Wellcome Open Research
based on 34 papers
Top 5%
0.7%
27
Journal of Public Health
based on 23 papers
Top 4%
0.7%